Clinical trials: Psychoses
Schizophrenia
Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
To evaluate the long-term safety and tolerability of pimavanserin after 52 weeks of adjunctive treatment in subjects with schizophrenia
- Trial name
- NCT03121586
- Testing
- Pimavanserin
- Where
- 161 sites in United States, Argentina and 12 more
- Volunteers
- 995 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizophrenia, Cognition
Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic
This is a study of the effects of tDCS on smoking, craving for cigarettes, cognition, and psychiatric symptoms in schizophrenic patients who are current smokers or have a history of regular cigarette smoking.
- Conditions
- Schizophrenia, Cognition, Cigarette Smoking
- Trial name
- TDCSSCHIZ (NCT02128919)
- Testing
- tDCS
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Alzheimer Disease
Valproate in Dementia (VALID)
The purpose of this trial is to demonstrate whether valproate therapy delays the emergence of agitation and/or psychosis in outpatients with probable Alzheimer's disease (AD) who have not experienced agitation and psychosis in…
- Trial name
- NCT00071721
- Testing
- Valproate
- Where
- 46 sites in United States
- Volunteers
- 313 people
- Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
Schizophrenia
PEARL Schizophrenia Maintenance
Lurasidone HCI is a compound that is FDA-approved for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that Lurasidone is effective in the long term maintenance treatment of schizophrenia.
- Trial name
- NCT01435928
- Testing
- Lurasidone
- Where
- 75 sites in United States, France and 5 more
- Volunteers
- 676 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Schizoaffective Disorder
Double-Blind Trial of a Probiotic Supplement to Reduce the Symptoms of Schizophrenia
The investigators intend to explore the hypothesis that symptoms of schizophrenia may be reduced by the administration of a probiotic supplement when used in addition to standard antipsychotic medications.
- Trial name
- NCT01242371
- Testing
- Probiotic Supplement
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Sheppard Pratt Health System
Schizophrenia
Switching Medication to Treat Schizophrenia
This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
- Trial name
- NCT00044655
- Testing
- Risperidone, Olanzapine, Ziprasidone
- Volunteers
- 219 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Schizophrenia, Schizo Affective Disorder
Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia
This application seeks to determine if neurophysiological metrics of memantine (MEM)-enhanced early auditory information processing (EAIP) in schizophrenia (SZ) mediate gains in auditory processing fidelity (APF) and auditory…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Healthy
- Trial name
- NCT03860597
- Testing
- Memantine
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Schizophrenia
rTMS as a Probe of Episodic Memory Neurocircuitry in Schizophrenia
This will be a single site pilot study. 30 subjects with Early Phase Psychosis (EPP), defined as medical record documentation of the onset of clinically significant psychotic symptoms within the past ten years, will be enrolled.
- Trial name
- rTMS-EM (NCT04182113)
- Testing
- 1 Hz rTMS Stimulation
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Indiana University
Schizophrenia, Schizophreniform Disorders
Horyzons: Implementation and Integration in Clinical Practice
The primary aim of this trial is evaluating the barriers and enablers of implementing a digital intervention with both therapeutic content and social networking, Horyzons, as part of clinical care in first episode psychosis (FEP)…
- Conditions
- Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorder, Unspecified or Other Psychotic Disorders
- Trial name
- NCT06002958
- Testing
- Horyzons USA
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of North Carolina, Chapel Hill
Social Cognition, Social Anxiety
Oxytocin and Social Cognition in Schizophrenia
Objective: Social Cognition and Emotional Intelligence have been shown to be deficient in patients with schizophrenia and these are not remediated by antipsychotic medications or psychosocial interventions.
- Conditions
- Social Cognition, Social Anxiety, Emotional Intelligence
- Trial name
- NCT00884897
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
Effects of Galantamine on Cognition
Schizophrenia is a chronic disorder with onset of psychosis occurring in late teen early twenties, with cognitive impairments and negative symptoms frequently emerging much earlier.
- Trial name
- NCT01100775
- Testing
- Galantamine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
Food Effect Study of Brexpiprazole Once-weekly (QW) Formulation in Patients With Schizophrenia
To investigate the effect of food on the pharmacokinetics of a single dose of brexpiprazole QW formulation.
- Trial name
- NCT06036108
- Testing
- OPC-34712FUM/ Brexpiprazole fumarate
- Where
- Japan
- Volunteers
- 59 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
Oculomotor and Spatial Cognition Deficits in Schizophrenia
DESCRIPTION: (Verbatim from the Applicant's Abstract) Abnormalities of eye movement control and spatial cognition are well-established deficits in schizophrenia.
- Trial name
- NCT00931996
- Testing
- Antipsychotic
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Illinois Chicago
Tobacco Smoking
E-cigarettes to Promote Smoking Reduction Among Individuals With Schizophrenia
The purpose of this study is to assess if access to an electronic nicotine delivery device, or e-cigarette, in addition to nicotine patch (21 mg) can help reduce cigarette smoking among individuals diagnosed with schizophrenia…
- Trial name
- NCT02918630
- Testing
- Nicotine Patch, E-cigarette
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- The University of Texas Health Science Center, Houston
Schizophrenia, Schizoaffective Disorder
A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)
A trial to compare if one 15 mg under the tongue tablet is equal to three 5 mg under the tongue tablets of Org 5222 (asenapine) in subjects with schizophrenia or schizoaffective disorder delivered.
- Trial name
- NCT01101464
- Testing
- Asenapine 3x5mg followed by 1x15mg, Asenapine 1x15mg followed by 3x5mg
- Volunteers
- 8 people
- Sponsor
- Organon and Co
Schizophrenia, Schizoaffective
An Open Trial of Cysteamine Treatment in Schizophrenia
The purpose of this study is to determine the tolerability of the medication cysteamine bitartrate on schizophrenia patients and to evaluate the effect of the medication on the symptoms of schizophrenia.
- Trial name
- NCT01139125
- Testing
- (Cystagon) Cysteamine Bitartrate
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Augusta University
Mental Disorder, Schizophrenia
A Trial to Assess a Wearable Patch's Functioning to Detect Medication Ingestion
The primary purpose of the study is to evaluate the positive detection accuracy (PDA) and detection latency measures of the D-Tect patch.
- Conditions
- Mental Disorder, Schizophrenia, Major Depressive Disorder, Bipolar I Disorder
- Trial name
- NCT06372210
- Testing
- Abilify MyCite®, D-Tect Patch
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Oxytocin and CBSST for People With Schizophrenia
A significant proportion of people with schizophrenia are characterized by impaired ability to socially engage with others, which may reflect social aversion secondary to defeatist beliefs; decreased motivation for social…
- Trial name
- NCT01752712
- Testing
- CBSST + Oxytocin
- Where
- 2 sites in United States
- Volunteers
- 83 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia
The purpose of this study is to investigate the effects of flexibly dosed Brexpiprazole monotherapy in the improvement of early-episode schizophrenia through the assessment of social functioning, efficacy, and tolerability.
- Trial name
- NCT02013622
- Testing
- Brexpiprazole
- Where
- 22 sites in United States
- Volunteers
- 49 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole
The purpose of this study is to compare retrospective hospitalization rates of schizophrenic patients treated with oral antipsychotics to prospective hospitalization rates of these patients treated with IM depot aripiprazole.
- Trial name
- ARRIVE- EU (NCT01509053)
- Testing
- Aripiprazole (Abilify®) IM Depot Injection, Oral aripiprazole
- Where
- 10 sites in Belgium, Bulgaria and 1 more
- Volunteers
- 30 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.